SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 32.09+4.5%3:55 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert K. who wrote (14649)9/16/2000 9:10:22 PM
From: Cacaito  Read Replies (3) of 17367
 
Again, no excess death, cause there is not proven decrease in mortality, even the probability of it is less now, cause it was a more striking difference in the pII with historical controls, now you have available "the largest data collected in this disorder" clearly showing no difference.

Bax could commit itself for the kids, and xoma, and with good $100 to $200 they could do a very good trial in Africa, plenty of subjects, not even need for individual informed consent, institutional one is accepted in Africa, immediate oral consent as minimal requirement pre or post use is possible. And this is FACT.

All the efforts to baxoma, show the money!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext